{"id":"https://openalex.org/W3018556339","doi":null,"title":"CheckMate-743 Trial of Nivolumab, Ipilimumab Meets Primary Endpoint in Mesothelioma Trial","display_name":"CheckMate-743 Trial of Nivolumab, Ipilimumab Meets Primary Endpoint in Mesothelioma Trial","alternate_titles":[],"publication_year":2020,"publication_date":"2020-04-21","ids":{"openalex":"https://openalex.org/W3018556339","mag":"3018556339"},"language":"en","primary_location":{"id":"mag:3018556339","doi":null,"is_oa":false,"landing_page_url":"https://www.cancernetwork.com/news/checkmate-743-trial-nivolumab-ipilimumab-meets-primary-endpoint-mesothelioma-trial","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null},"parent_works":[],"lineage":["https://openalex.org/W3018556339"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5051642189","display_name":"Hannah Slater","orcid":"https://orcid.org/0000-0003-4291-7899","observed_orcids":["https://orcid.org/0000-0003-4291-7899"]},"institutions":[],"countries":[],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Hannah Slater","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":["https://openalex.org/A5051642189"],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11026","display_name":"Occupational and environmental lung diseases","score":0.9976000189781189,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11026","display_name":"Occupational and environmental lung diseases","score":0.9976000189781189,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.00139999995008111,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12064","display_name":"Intraperitoneal and Appendiceal Malignancies","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/nivolumab","display_name":"nivolumab","score":0.9190000295639038},{"id":"https://openalex.org/keywords/ipilimumab","display_name":"ipilimumab","score":1.0},{"id":"https://openalex.org/keywords/malignant-pleural-mesothelioma","display_name":"malignant pleural mesothelioma","score":0.9610000252723694},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.9160000085830688},{"id":"https://openalex.org/keywords/combination-immunotherapy","display_name":"combination immunotherapy","score":0.8410000205039978},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.8579999804496765},{"id":"https://openalex.org/keywords/primary-endpoint","display_name":"primary endpoint","score":0.640999972820282}],"concepts":[{"id":"https://openalex.org/C2781433595","wikidata":"https://www.wikidata.org/wiki/Q2459042","display_name":"Ipilimumab","level":4,"score":0.8862912654876709},{"id":"https://openalex.org/C2780030458","wikidata":"https://www.wikidata.org/wiki/Q7041828","display_name":"Nivolumab","level":4,"score":0.8762660026550293},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.692758321762085},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.6613823175430298},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5437880158424377},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.483849436044693},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.468772828578949},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.1786622405052185},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.1774926483631134}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:3018556339","doi":null,"is_oa":false,"landing_page_url":"https://www.cancernetwork.com/news/checkmate-743-trial-nivolumab-ipilimumab-meets-primary-endpoint-mesothelioma-trial","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.98580002784729,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W7131797084","https://openalex.org/W3122627530","https://openalex.org/W4394878936","https://openalex.org/W3126405072","https://openalex.org/W4400143079","https://openalex.org/W7131782268","https://openalex.org/W2765874934","https://openalex.org/W2908887190","https://openalex.org/W4412979354","https://openalex.org/W4210792133"],"abstract_inverted_index":{"The":[0],"trial":[1],"evaluating":[2],"nivolumab":[3],"in":[4,8],"combination":[5],"with":[6],"ipilimumab":[7],"previously":[9],"untreated":[10],"malignant":[11],"pleural":[12],"mesothelioma":[13],"met":[14],"its":[15],"primary":[16],"endpoint":[17],"of":[18],"overall":[19],"survival.":[20]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W3018556339","counts_by_year":[],"updated_date":"2026-11-21T10:27:49.728292","created_date":"2020-05-01T00:00:00"}
